Breaking up with Pfizer is hard to do, Zoetis chief says, but worth it

Why do Russians prefer cats to dogs? Which livestock drugs are growing fastest? And what are the benefits of being separate from Pfizer? Juan Ramón Alaix, CEO of the Zoetis ($ZTS) animal health business Pfizer ($PFE) spun off early this year, answers these and other questions in a Wall Street Journal interview. Report (sub. req.)

Suggested Articles

Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has shown a clinical benefit for HIV patients.

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.